Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Cambridge Heart, Inc., today announced the first patient enrollments in the MTWA-CAD study (Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients with Known or Suspected Coronary Artery Disease).

7 Jul 2010

Physio-Control initiates field correction on certain LIFEPAK 20/20e defibrillator/monitors

Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc.,, announced the company's recent initiation of a field correction on certain LIFEPAK 20/20e defibrillator/monitors manufactured prior to January 9, 2009. Analysis conducted by Physio-Control verified a possible battery (DC) power malfunction on the affected devices. In the malfunction scenario, a loss of battery power may occur while the unit is in operation.

3 Jul 2010

Cambridge Heart announces CMS reimbursement modification for MTWA test

Cambridge Heart, Inc., today announced that effective July 1, 2010, the Centers for Medicare and Medicaid Services (CMS) will allow full reimbursement for both a Microvolt T-Wave Alternans (MTWA) test and a stress test when both tests are performed during the same patient visit. The CMS update removes a previous restriction that substantially limited reimbursement when a patient underwent an MTWA test on the same day as the patient underwent a standard cardiac stress test, echocardiography stress test, nuclear cardiac stress test, or pulmonary stress test.

2 Jul 2010

Saint Thomas Chest Pain Network awarded HRSA grant for placement of AEDs in 14 rural communities

The Saint Thomas Chest Pain Network, a network service provided by Saint Thomas Health Services, was recently awarded a $100,000 Health Resources and Services Administration grant from the United States Department of Health and Human Services for the placement of full-rescue Automated External Defibrillators in 14 rural communities throughout the network.

28 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Study: Traditional methods for assessing patients after cardiac arrest may underestimate chances for survival

Traditional methods for assessing patients after cardiac arrest may be underestimating their chances for survival and good outcomes, according to a new study by University of Pittsburgh School of Medicine researchers now available online in the journal Resuscitation.

24 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

AACN endorses scientific statement on prevention of TdP

The American Association of Critical-Care Nurses recently endorsed "Prevention of Torsades de Pointes in Hospital Settings," a scientific statement from the American Heart Association, Dallas, and American College of Cardiology Foundation, Washington, D.C.

10 Jun 2010

New AAN guideline provides step-by-step process for determining brain death in adults

In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Arrhythmia Alliance launches 'Know Your Pulse' global awareness campaign on World Heart Rhythm Week

Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm disorders. To raise awareness of the importance of pulse checking and to inform people about how to take their pulse, the Arrhythmia Alliance will open 2010 World Heart Rhythm Week (7-13 June) with the launch of the global awareness campaign 'Know Your Pulse'.

7 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

High oxygen delivery after postcardiac arrest leads to higher rate of death in hospitals

Patients who have excessive oxygen levels in arterial blood (hyperoxia) following resuscitation from cardiac arrest have a higher rate of death in the hospital than similar patients without arterial hyperoxia, according to a study in the June 2 issue of JAMA.

2 Jun 2010

Odds of surviving cardiac arrest may depend on neighborhood: Study

The odds of surviving cardiac arrest may depend on which part of town you call home and whether anyone in the neighborhood comes to your rescue by attempting to perform cardiopulmonary resuscitation, according to a first-of-its-kind study in the June issue of the Annals of Internal Medicine.

1 Jun 2010

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Weill Cornell Medical College today celebrated the start of construction on its new Medical Research Building, a state-of-the-art facility that will more than double the institution's existing research space. The 18-story, $650 million building is the centerpiece of Weill Cornell's $1.3 billion Discoveries that Make a Difference Campaign, the country's largest for a medical college. A total of $1 billion has been raised toward this goal in a record time of less than four years.

27 May 2010

Half the high schools in Toronto do not train students how to perform CPR: Study

Almost half the high schools in Toronto do not teach students how to perform cardio-pulmonary resuscitation (CPR), even though it's part of the Grade 9 curriculum and studies have shown it can greatly increase the survival rates of people who suffer heart attacks outside of hospitals.

26 May 2010

Free emergency care training to address sudden cardiac arrest

The National Safety Council today announced it will offer free emergency care training during National CPR & AED Awareness Week (June 1-7). First Aid and CPR with AED is a three-hour online course that teaches participants how to respond should someone need assistance. First aid topics include breathing emergencies, sudden illness and injury, and bleeding.

26 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Physio-Control initiates field correction on certain LIFEPAK 20/20e defibrillator/monitors

Cambridge Heart announces CMS reimbursement modification for MTWA test

Saint Thomas Chest Pain Network awarded HRSA grant for placement of AEDs in 14 rural communities

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Study: Traditional methods for assessing patients after cardiac arrest may underestimate chances for survival

Women who experience early menopause may have cardiovascular disease later in life: Study

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

AACN endorses scientific statement on prevention of TdP

New AAN guideline provides step-by-step process for determining brain death in adults

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Arrhythmia Alliance launches 'Know Your Pulse' global awareness campaign on World Heart Rhythm Week

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

High oxygen delivery after postcardiac arrest leads to higher rate of death in hospitals

Odds of surviving cardiac arrest may depend on neighborhood: Study

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Half the high schools in Toronto do not train students how to perform CPR: Study

Free emergency care training to address sudden cardiac arrest

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in